Biotechnology company EpiBiologics has appointed Dr Ann Lee-Karlon as CEO, president and a member of its board.
Lee-Karlon will handle activities related to the expansion of the EpiTAC platform, a modular antibody-based system. She will establish partnerships and create a bispecific antibody protein degrader therapeutics pipeline.
Lee-Karlon previously worked as chief operating officer at Altos Labs. She has also served as senior vice-president at Genentech.
Lee-Karlon stated: “EpiBiologics has developed a groundbreaking platform to target membrane and extracellular proteins, leveraging a novel atlas of tissue-specific degrader antibodies.
“Targeted extracellular protein degradation represents a new therapeutic modality with a wide range of applications, including cancer, immunology and neurological diseases.”
EpiBiologics has also raised $23m in a new Series A financing round, taking the total Series A funds to $73m.
New investors Digitalis Ventures and Taiho Ventures and current investor Codon Capital provided the latest financing.
EpiBiologics was launched in March 2023 with Series A financing of $50m from investors Polaris Partners, Mubadala Capital, Vivo Capital and GV.
The EpiTAC platform aids in the tissue-specific breakdown of disease-causing membrane and extracellular proteins.
Digitalis Ventures partner Samuel Bjork stated: “EpiBiologics has made tremendous progress with its leading-edge EpiTAC platform, which will unravel the underlying intricacies of disease biology to build precision therapeutics.”
